For patients receiving adjuvant trastuzumab for HER2+ positive breast cancer, if a patient misses a dose, do you make up that dose or stop at 1 year mark without making the dose up?

I would typically make up the dose. My reasoning is that the goal of treatment is to increase probability of cure. We know from prior adjuvant trials that decreasing the relative dose intensity (defined as the dose delivered over time divided by the standard, protocol-defined dose of regimen over ti...